- Molecular NameDexamethasone
- SynonymDesametasone; Desametasone [DCIT]; Desamethasone; Dexametasona [INN-Spanish]; Dexamethasone Acetate; Dexamethasone Sodium Phosphate; Dexamethasonum [INN-Latin]; Dexamethazone; Fluormethylprednisolone
- Weight392.467
- Drugbank_IDDB01234
- ACS_NO50-02-2
- Show 2D model
- LogP (experiment)1.83
- LogP (predicted, AB/LogP v2.0)1.99
- pkaN/A
- LogD (pH=7, predicted)1.99
- Solubility (experiment)0.0963 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.94
- LogSw (predicted, AB/LogsW2.0)0.07
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds2
- TPSA94.83
- StatusFDA approved
- AdministrationOral, IV, IM, SC and IO
- PharmacologyA potent synthetic member of the glucocorticoid class of steroid hormones. It acts as an anti-inflammatory and immunosuppressant. Its potency is about 20-30 times that of hydrocortisone and 4-5 times of prednisone.
- Absorption_value90.0
- Absorption (description)Rapidly absorbed after oral administration.
- Caco_2N/A
- Bioavailability78.0
- Protein binding67.0
- Volume of distribution (VD)1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, 1.2.
- Metabollsmhepatic
- Half life2~5 h
- ExcretionUp to 65% of a dose is excreted in the urine in 24 h, mainly as metabolites.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
- LD50 (rat)LD50: >3 gm/kg
- LD50 (mouse)N/A